Jeffrey Allen Bailey is Director of Aurinia Pharmaceuticals Inc.. Currently has a direct ownership of 25,491 shares of AUPH, which is worth approximately $225,850. The most recent transaction as insider was on Nov 21, 2024, when has been sold 12,135 shares (Common Shares) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 25.5K
n/a 3M change
n/a 12M change
Total Value Held $225,850

Jeffrey Allen Bailey Transaction History

Date Transaction Value Shares Traded Shares Held Form
Nov 21 2024
BUY
Grant, award, or other acquisition
-
12,135 Added 32.25%
25,491 Common Shares
Nov 11 2024
SELL
Open market or private sale
$38,415 $8.43 p/Share
4,557 Reduced 25.44%
13,356 Common Stock
Nov 08 2024
BUY
Exercise of conversion of derivative security
-
17,913 Added 50.0%
17,913 Common Stock

Also insider at

BDSI
BIODELIVERY SCIENCES INTERNATIONAL INC Healthcare
THW
Tekla World Healthcare Fund Financial Services
ALRN
AILERON THERAPEUTICS INC Healthcare
JAB

Jeffrey Allen Bailey

Director
Boston, MA

Track Institutional and Insider Activities on AUPH

Follow Aurinia Pharmaceuticals Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AUPH shares.

Notify only if

Insider Trading

Get notified when an Aurinia Pharmaceuticals Inc. insider buys or sells AUPH shares.

Notify only if

News

Receive news related to Aurinia Pharmaceuticals Inc.

Track Activities on AUPH